Cargando…
Anticoagulation for Stroke Prevention of Concomitant Atrial Fibrillation and End-Stage Renal Disease: Insights of Cardiologists and Nephrologists From India
Introduction Patients with concomitant atrial fibrillation (AF) and end-stage renal disease (ESRD) are at increased risk of thrombosis and bleeding. Diligent anticoagulant therapy that prevents major bleeding is essential for stroke prevention. There is a dearth of evidence and guidance on anticoagu...
Autores principales: | ES, Swetha, Taur, Santosh, Kulkarni, Namrata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857051/ https://www.ncbi.nlm.nih.gov/pubmed/36694536 http://dx.doi.org/10.7759/cureus.32788 |
Ejemplares similares
-
A Cardiologists’ Survey on the Use of Anticoagulants and Antiplatelets in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Those Undergoing Percutaneous Coronary Intervention in India
por: Kulkarni, Namrata, et al.
Publicado: (2023) -
Same rhythm, different song—approaches to atrial fibrillation management by cardiologists and nephrologists
por: Mark, Patrick B., et al.
Publicado: (2020) -
Comparison Between Oral Anticoagulation and Left Atrial Appendage Occlusion in the Prevention of Stroke With Regard to Non-Valvular Atrial Fibrillation
por: Sandhu, Osama, et al.
Publicado: (2020) -
Expert Opinion on the Use of Novel Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation for the Primary Care Setting in India: A Literature Review
por: Dalal, Jamshed, et al.
Publicado: (2022) -
Ischemic Stroke in a Patient With Atrial Tachycardia, Methylenetetrahydrofolate Reductase Mutation and New-Onset Atrial Fibrillation: Is Early Initiation of Anticoagulation Therapy Indicated?
por: Eyituoyo, Harry O, et al.
Publicado: (2020)